



John E. Burke

303.357.1667
jburke@merchantgould.com

Denver Office
1050 Seventeenth Street
Suite 1950
Denver, CO 80265 USA

303.357.1670 phone
303.357.1671 fax

John Burke has 20 years of experience advising clients on intellectual property matters with a focus on chemical patent law practice, including pharmaceuticals, biotechnology, genomics and medical devices, including related patent strategy, opinion work, licensing, due diligence, prosecution and litigation support. John was formerly a shareholder with Greenberg Traurig; General Counsel for Deltagen, Inc., a functional genomics and drug discovery company located in the San Francisco bay area; chairman of the patent law group for the San Diego office of Pillsbury Winthrop; corporate patent counsel for Cortech, Inc., a Denver based biopharmaceutical company; and an associate with the New York office of Morgan & Finnegan.

Representative clients include Novartis-Sandoz, Covidien (Tyco Healthcare), Thermo Fisher Scientific, Merck, Gen-Probe, Myogen, Sunesis Pharmaceuticals, Deltagen, BioAtla, Diversa, Sierra Neuropharmaceuticals, Leuchemix, Acadia Pharmaceuticals, Ceptyr Pharmaceuticals, Alliance Pharmaceuticals, FibroGen, Cortech, Angiogenix, Nuvelo, Enturia (Medi-Flex), Trellia Networks, Archemix, Accutera, University of Colorado and University of Kansas

Education

Rutgers College of Engineering
B.S., Chemical/Biochemical Engineering, 1983

Rutgers School of Law - Camden
J.D., 1990

Bar Admissions

Colorado
California
New York
U.S. Court of Appeals for the Federal Circuit
U.S. Supreme Court
U.S. Patent and Trademark Office

www.merchantgould.com

Atlanta

Denver

Knoxville

Madison

Minneapolis

Omaha

Seattle

Washington DC

John E. Burke (Continued)

Honors

The Best Lawyers in America (Intellectual Property Law and Biotechnology) 2010
Colorado Super Lawyer (Intellectual Property) 2006-10

Professional Affiliations

American Bar Association
Federal Circuit Bar Association
Licensing Executive Society
American Intellectual Property Law Association

Articles

"Prior Art by Admission Doctrine: Judicially Created Private Prior Art," *The Federal Circuit Bar Journal*, June 2004

"Joint Venture Companies Must Now Disclose Confidential Information During Patent Prosecution; The Oddzon Decision" *Pillsbury Winthrop Shaw Pittman* (1999)

"Overview: Bradykinin Receptor Antagonists," *Expert Opinions in Therapeutic Patents* 5 (4):331-340 (1995)

www.merchantgould.com

Atlanta

Denver

Knoxville

Madison

Minneapolis

Omaha

Seattle

Washington DC